When compared to the results of other well-characterized methylation markers in additional forms of cancer (i.e. MGMT in glioblastomas and GSTP1 in prostate cancers) [31,32] the outcomes are extremely encouraging and further work on larger cohorts, maybe in combination with other leukemia-specific methylation markers, are required to confirm if our observations can be useful in a clinical setting. The gene discussed is MGMT; the disease is prostate cancer.